- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Biocon Limited — Updates, 23-12-2025: Press Release
23-12-2025 | 09:11 am
23-12-2025 | 09:11 am
Biocon Biologics gains full global rights for biosimilar Adalimumab (Hulio®), taking over manufacturing and commercialization from FKB. This expands control, aiming for enhanced flexibility and cost efficiency in its immunology portfolio.
No comments yet. Be the first to comment!